{"entity":{"id":"csco-guidelines","kind":"collection","name":"CSCO guidelines (China)","aka":[],"tldr":"CSCO guidelines are China's national oncology guidelines, covering about 30 cancers and updated annually. They grade each recommendation by both evidence level and affordability under China's reimbursement list, and they cover Chinese-developed drugs (PD-1 inhibitors, ADCs) and cancers common in China (nasopharyngeal, oesophageal, liver, gastric) years before Western guidelines.","summary":"CSCO guidelines (since 2016 in current form) use a two-dimensional system: evidence level (1A-3) and recommendation grade (I basic, II optional, III) that considers drug accessibility, cost and reimbursement in China's National Reimbursement Drug List. They cover Chinese approvals (toripalimab, camrelizumab, sintilimab, tislelizumab, disitamab vedotin, furmonertinib, savolitinib) years before Western uptake and are published in English for several tumours (e.g. joint CSCO/ASCO NPC guideline 2021). Read with the NMPA approvals list for a view of the world's second-largest oncology market.","asOf":"2026-09-08","links":[{"label":"CSCO (page moved; nearest live section)","url":"https://www.csco.org.cn/"},{"label":"CSCO/ASCO NPC guideline (JCO 2021)","url":"https://doi.org/10.1200/JCO.20.03237"}],"tags":["gap-fill","guidelines"],"related":["nccn","esmo-guidelines","nasopharyngeal","esophageal","hcc","gastric"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["toripalimab","camrelizumab","tislelizumab","penpulimab"],"companies":[],"institutions":["sysucc","cams-cancer-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"url":"https://www.csco.org.cn/","holds":"Chinese Society of Clinical Oncology guidelines for ~30 cancers, graded by evidence and by accessibility/affordability in China (basic vs optional strategies), updated annually.","license":"CSCO","maintainer":"Chinese Society of Clinical Oncology"},"route":"/collections/csco-guidelines/","neighbours":{"collection":[{"id":"esmo-guidelines","kind":"collection","name":"ESMO Clinical Practice Guidelines & MCBS","route":"/collections/esmo-guidelines/"},{"id":"nccn","kind":"collection","name":"NCCN Guidelines","route":"/collections/nccn/"}],"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"nasopharyngeal","kind":"cancer","name":"Nasopharyngeal carcinoma","route":"/cancers/nasopharyngeal/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"drug":[{"id":"camrelizumab","kind":"drug","name":"Camrelizumab","route":"/drugs/camrelizumab/"},{"id":"penpulimab","kind":"drug","name":"Penpulimab","route":"/drugs/penpulimab/"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"},{"id":"toripalimab","kind":"drug","name":"Toripalimab","route":"/drugs/toripalimab/"}],"institution":[{"id":"cams-cancer-hospital","kind":"institution","name":"Cancer Hospital, Chinese Academy of Medical Sciences","route":"/institutions/cams-cancer-hospital/"},{"id":"csco","kind":"institution","name":"Chinese Society of Clinical Oncology","route":"/institutions/csco/"},{"id":"pumch","kind":"institution","name":"Peking Union Medical College Hospital","route":"/institutions/pumch/"},{"id":"pku-cancer-hospital","kind":"institution","name":"Peking University Cancer Hospital","route":"/institutions/pku-cancer-hospital/"},{"id":"sysucc","kind":"institution","name":"Sun Yat-sen University Cancer Center","route":"/institutions/sysucc/"},{"id":"tmucih","kind":"institution","name":"Tianjin Medical University Cancer Institute and Hospital","route":"/institutions/tmucih/"}],"roadmap":[{"id":"global-access-roadmap","kind":"roadmap","name":"Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation","route":"/roadmaps/global-access-roadmap/"}]}}